Multiple Sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
Intervention 1: Control group: mitoxantrone 20 mg as well as methylprednisolone 500 mg monthly for 6 consecutive months. Intervention 2: Intervention group: mitoxantrone 20 mg monthly for 6 consecutiv
Treatment - Drugs
Control group: mitoxantrone 20 mg as well as methylprednisolone 500 mg monthly for 6 consecutive months
Intervention group: mitoxantrone 20 mg monthly for 6 consecutive months
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: presence of progressive MS, age between 20 to 50 Exclusion criteria: Age below 20 or above 50, Immune deficiency, cancer, Pregnancy or breast feeding, Renal or heart failure, Leukopenia during the injection (the reduction of neutrophils to less than 1500/ml), having received corticosteroids within 6 months before the trial
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI plaque numbers. Timepoint: 6 months and 1 year after the intervention. Method of measurement: Based on MRI imaging.;Expanded Disability Status Scale (EDSS). Timepoint: 6 months and 1 year after the intervention. Method of measurement: Based on definit idex. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Mellat Ardekani
Yazd Univesity of Medical Sciences
Outcome results
None listed